Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor

Phase 1 Not yet recruiting 228 enrolled Danatlas Pharmaceuticals Co., Ltd

Non-randomizedSequentialOpen-labelTreatment

Summary

The primary objective of the study is to evaluate the safety, tolerability, PK, and preliminary efficacy of a Polθ Inhibitor DAT-1604 in patients with advanced/metastatic solid tumors, which is refractory to standard therapies, or for which no standard therapies exist.

Timeline

Start: 2025-07-31
Primary completion: 2026-12-30
Completion: 2028-07-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DAT-1604	Small molecule	—	Oral

Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor

Summary

Timeline

Drugs

Indications